Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study

Abstract Background Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, widely used for type 2 diabetes and cardiorenal conditions, may induce erythrocytosis, potentially increasing cardiovascular risk. This study investigates its prevalence, risk factors, and thrombotic implications. Methods In a s...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ji Yun Lee, Ju-Hyun Lee, Eun-Jung Jung, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-07-01
coleção:	Cardiovascular Diabetology
Assuntos:	SGLT-2 inhibitors Diabetes mellites Erythrocytosis Thrombosis
Acesso em linha:	https://doi.org/10.1186/s12933-025-02805-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!